EMA consults on how to improve monitoring of clinical trials in third countries
This article was originally published in SRA
Executive Summary
The European Medicines Agency has issued for public consultation a reflection paper that considers how to better monitor clinical trials that are conducted in third countries (ie outside the European Economic Area) and used to support marketing authorisation applications submitted to the agency1,2.